Pharmacogenomics in the Management of Hypertension explores genetic factors influencing responses to antihypertensive medications. It discusses genetic predictors of efficacy and adverse effects in treatments like ACE inhibitors, beta-blockers, and diuretics. The book emphasizes personalized approaches to optimize blood pressure control and reduce cardiovascular risks. Suitable for cardiologists and geneticists, it advances tailored hypertension management through genetic insights.
Rachel Watson integrates pharmacogenomics into the management of hypertension-related skin conditions, enhancing treatment efficacy and safety. Her research focuses on how genetic variations influence responses to antihypertensive medications used in treating hypertension-induced dermatitis and rosacea. Rachel has published extensively on personalizing hypertension pharmacotherapy to improve dermatological outcomes through pharmacogenomic testing. She also provides guidelines for clinicians to utilize pharmacogenomic insights in managing hypertension-related skin conditions, promoting personalized and effective dermatological care through genetic-informed hypertension management strategies.